Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.

Abstract

Objective: To evaluate sintilimab compared with other PD-L1 inhibitors in combination with platinum-based doublet chemotherapy as the first-line treatment of non-squamous non-small-cell lung cancer. Methods: A frequentist meta-analysis was used to compare outcomes, including progression-free survival, overall survival, objective response rate, time to response and safety profile. Results: The sintilimab combination arm had progression-free survival comparable to that of the pembrolizumab combination arm (hazard ratio [HR] = 1.00; 95% CI: 0.71, 1.41), the atezolizumab combination arm (HR: 0.81; 95% CI: 0.59, 1.10), the tislelizumab combination arm (HR: 0.75; 95% CI: 0.48, 1.16), the camrelizumab combination arm (HR: 0.80; 95% CI: 0.54, 1.20) and the nivolumab combination arm (HR: 0.72; 95% CI: 0.51, 1.02). Any grade or grade ≥3 adverse event was comparable between PD-L1 inhibitors. Conclusion: Sintilimab showed a comparable efficacy and safety profile when compared with other PD-L1 inhibitors combined with platinum-based doublet chemotherapy as the first-line treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer.

• Authors: Lei Zhang, Yijiao Qian, Jinnan Li, Chenwei Cui, Lu Chen, Shuli Qu, Shun Lu
• Journal: Future oncology (London, England) (Future Oncol) Vol. 18 Issue 15 Pg. 1896-1905 (May 2022) ISSN: 1744-8301 [Electronic] England
• PMID: 35311347 (Publication Type: Journal Article, Meta-Analysis, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• B7-H1 Antigen
• Immune Checkpoint Inhibitors
• sintilimab

Topics

• Antibodies, Monoclonal, Humanized
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• B7-H1 Antigen
• Carcinoma, Non-Small-Cell Lung (pathology)
• Humans
• Immune Checkpoint Inhibitors
• Lung Neoplasms (pathology)